Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

For patients already receiving metformin therapy, the starting dose should be based on the patient's current metformin regimen. The total daily dose should not exceed 100 mg sitagliptin and 2000 mg metformin.

Metformin and sitagliptin are known to be substantially excreted by the kidney. The risk of metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Thus, patients with serum creatinine levels above the upper limit of normal for their age should not receive JANUMET. In the elderly, JANUMET should be carefully titrated to establish the minimum dose for adequate glycemic effect, because aging can be associated with reduced renal function. Any dose adjustment should be based on a careful assessment of renal function. Before initiation of therapy with JANUMET and at least annually thereafter, renal function should be assessed and verified as normal.

Selected cautionary information for JANUVIA

Because JANUVIA is renally eliminated, and to achieve plasma concentrations of JANUVIA similar to those in patients with normal renal function, a dosage adjustment is recommended in patients with moderate renal insufficiency and in patients with severe renal insufficiency or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis. Safety and effectiveness of JANUVIA in pediatric patients have not been established. There are no adequate and well-controlled studies in pregnant women. JANUVIA should be used during pregnancy only if clearly needed. Caution should be exercised when JANUVIA is administered to a nursing woman. In clinical trials, JANUVIA demonstrated an overall incidence of side effects comparable to placebo. The most common side effects reported with JANUVIA (greater than or equal to 5 percent and higher than placebo) were stuffy or runny nose and sore throat, upper respiratory infection, and headache.

Selected cautionary information for JANUMET

JANUMET should b
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:9/23/2014)... 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a ... diseases and cholesterol gallstones, announced today that the ... approved its request for Fast Track Designation of ... Non-Alcoholic Steato-Hepatitis, or NASH.  FDA ...
(Date:9/23/2014)... 2014  MEDIMETRIKS PHARMACEUTICALS today announced that ... have been elected to Medimetriks, Board of Directors ... who will serve on Medimetriks, Audit Committee, brings ... the Company.  Mr. Lary is currently Managing Director, ... institutional investment firm.  Mr. Lary is responsible for ...
(Date:9/23/2014)... 23, 2014  Vesselon, Inc. today announced the appointment ... effective September 15, 2014. Dr. Raths, appointment follows Vesselon,s ... agent to market a private preferred Series A round ... treatment. "Jurgen,s deep experience across multiple functional ... asset to Vesselon as we develop our device that ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- Few children ... undergo behavioral therapy, and the rates vary six-fold ... study finds. Medication alone can manage symptoms ... better if they also receive behavioral therapy (psychotherapy), ... analyzed data in more than 1,500 counties across ...
(Date:9/23/2014)... grow up to earn up to 18 percent less ... Lundborg of Lund University, Paul Nystedt of Jnkping University ... all in Sweden. The team compared extensive information from ... the results are published in Springer,s journal Demography ... 145,193 Swedish-born brothers who enlisted in the Swedish National ...
(Date:9/23/2014)... 23, 2014 Vancouver Electrician Contractors, Pro ... offering commercial electrical services in Vancouver, BC. The company ... it is a small maintenance project or a large-scale ... package to meet the needs of the individual commercial ... will be of an affordable price. As a result, ...
(Date:9/23/2014)... 2014 The Sloane Clinic™, a ... and Malaysia providing advanced aesthetic dermatology and cosmetic ... its impressive skin care repertoire. Specially formulated with ... against the evil forces of aging, acne and ... this new addition is revolutionizing the way we ...
(Date:9/23/2014)... York (PRWEB) September 23, 2014 Risperdal ... courts around the country, Bernstein Liebhard LLP reports. According ... District of Florida on September 19th, the Court has ... case filed in that jurisdiction on behalf of a ... other complications due to his use of Risperdal. In ...
Breaking Medicine News(10 mins):Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2Health News:Note to young men: Fat doesn't pay 2Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 3
... , CAMBRIDGE, Mass., Sept. 9 ... enterprise content compliance software solutions for ... Software-as-a-Service (SaaS) solution for managing clinical trial disclosure requirements. The ... a robust offering that automates compliance with global regulatory mandates ...
... , NASHVILLE, Tenn., Sept. 9 ... provider of revenue and payment cycle management solutions, today ... Healthcare Network Accreditation Program (HNAP) from the Electronic Healthcare ... in health data processing and transactions and indicates compliance ...
... STOCKHOLM, September 9 Karolinska Development ... that will commercialize its,dermatology and wound healing opportunities as ... all of its,holdings from its five dermatology and wound ... company. , "This is a ...
... New Hearing ... ... website www.AdviceOnHearingAids.com is proving to be a valuable and informative resource for consumers ... aids, and so many different brands, styles, types of technology, and opinions about which one ...
... , TITUSVILLE, N.J., Sept. 9 Attention ... percent of children(1) and 4 percent of adults in the U.S.(2) ... 20 percent of U.S. school-aged children meet the Diagnostic and Statistical ... receiving an ADHD diagnosis.(3) Meanwhile, it is estimated that just 15 ...
... , , , HERMOSA ... empower parents across the globe to participate in the fight against AIDS ... ... go outside, go discover, go experience. Through the new partnership with ... to not only improve their own lives, but also the lives of ...
Cached Medicine News:Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 2Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 3Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 4Health News:Emdeon Receives EHNAC Healthcare Network Re-accreditation 2Health News:Emdeon Receives EHNAC Healthcare Network Re-accreditation 3Health News:Karolinska Development Introduces New Concept for Development of its Dermatology and Wound Healing Portfolio 2Health News:Help for Hearing Loss - Now Available Online 2Health News:Help for Hearing Loss - Now Available Online 3Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 2Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 3Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 4Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 5Health News:'Go and Good Things Happen' with (BUGABOO)(RED) 2Health News:'Go and Good Things Happen' with (BUGABOO)(RED) 3Health News:'Go and Good Things Happen' with (BUGABOO)(RED) 4
... is an inverted system microscope ... imaging needs of high-level laboratory ... and the excellence of its ... cell culture observation to fluorescence ...
... The SZX microscope system is ... the Olympus line. Long working distance, ... and easy operation are matched by ... motorized components giving the SZX great ...
... The MicroFire is a 2-megapixel, 12-bit FireWire digital camera. ... be acquired effortlessly. Imaging has never been this easy! ... CCD - 2/3" Color ... Time - 500 microseconds - 60 seconds ...
... a Progressive Scan 1/2" CCD with square pixels ... (V) SXGA. Whats more the XCD-SX910CR uses a ... "Bayer filter") and outputs the "raw color" pixel ... converted to a color image on the computer. ...
Medicine Products: